Axovant Gene Therapies Ltd (NASDAQ:AXGT) was the recipient of a significant drop in short interest during the month of August. As of August 15th, there was short interest totalling 1,061,600 shares, a drop of 17.1% from the July 15th total of 1,280,600 shares. Currently, 2.2% of the shares of the company are short sold. Based on an average trading volume of 662,600 shares, the short-interest ratio is presently 1.6 days.

Shares of NASDAQ AXGT traded down $0.23 during trading on Wednesday, hitting $7.63. 78,183 shares of the company traded hands, compared to its average volume of 386,879. The businesss fifty day moving average is $6.87 and its 200 day moving average is $4.87. Axovant Gene Therapies has a fifty-two week low of $3.81 and a fifty-two week high of $20.80. The firm has a market capitalization of $178.68 million, a price-to-earnings ratio of -0.95 and a beta of 1.26. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.70 and a current ratio of 1.70.

Axovant Gene Therapies (NASDAQ:AXGT) last announced its quarterly earnings data on Friday, August 9th. The company reported ($1.23) earnings per share for the quarter, beating the consensus estimate of ($1.34) by $0.11. On average, analysts predict that Axovant Gene Therapies will post -4.25 EPS for the current year.

Several institutional investors and hedge funds have recently bought and sold shares of AXGT. Sphera Funds Management LTD. acquired a new stake in shares of Axovant Gene Therapies in the 1st quarter worth about $6,794,000. Primecap Management Co. CA acquired a new stake in shares of Axovant Gene Therapies in the 1st quarter worth about $1,400,000. BlackRock Inc. acquired a new stake in shares of Axovant Gene Therapies in the 2nd quarter worth about $1,482,000. Marshall Wace LLP acquired a new stake in shares of Axovant Gene Therapies in the 1st quarter worth about $272,000. Finally, Jane Street Group LLC raised its holdings in shares of Axovant Gene Therapies by 28.8% in the 2nd quarter. Jane Street Group LLC now owns 46,455 shares of the companys stock worth $289,000 after acquiring an additional 10,375 shares during the last quarter. Institutional investors own 13.48% of the companys stock.

Axovant Gene Therapies Company Profile

Axovant Gene Therapies Ltd., a clinical-stage gene therapy company, focuses on developing a pipeline of product candidates for debilitating neurological and neuromuscular diseases. The company's current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis, Parkinson's disease, oculopharyngeal muscular dystrophy, amyotrophic lateral sclerosis, and frontotemporal dementia.

Featured Story: Earnings Reports

Receive News & Ratings for Axovant Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.

Here is the original post:
Axovant Gene Therapies Ltd (NASDAQ:AXGT) Short Interest Update - Tech Know Bits

Comments are closed.